Altium Capital Management LLC Has $4.54 Million Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Altium Capital Management LLC raised its holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 97.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 385,000 shares of the biopharmaceutical company's stock after buying an additional 190,000 shares during the quarter. Altium Capital Management LLC owned 3.16% of Corbus Pharmaceuticals worth $4,543,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its stake in Corbus Pharmaceuticals by 27.0% during the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock valued at $114,000 after acquiring an additional 1,172 shares during the period. Wells Fargo & Company MN raised its stake in shares of Corbus Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 2,195 shares in the last quarter. FMR LLC boosted its position in shares of Corbus Pharmaceuticals by 33.0% during the 3rd quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company's stock valued at $207,000 after acquiring an additional 2,486 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Corbus Pharmaceuticals by 4.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 97,882 shares of the biopharmaceutical company's stock worth $1,155,000 after purchasing an additional 4,239 shares in the last quarter. Finally, Avanza Fonder AB acquired a new stake in Corbus Pharmaceuticals during the fourth quarter valued at approximately $84,000. 64.64% of the stock is owned by institutional investors.

Corbus Pharmaceuticals Stock Up 2.7 %

CRBP stock traded up $0.18 during midday trading on Wednesday, reaching $6.87. The company's stock had a trading volume of 62,799 shares, compared to its average volume of 363,751. The business's 50-day simple moving average is $6.45 and its 200-day simple moving average is $11.82. The stock has a market cap of $84.03 million, a PE ratio of -1.46 and a beta of 3.12. Corbus Pharmaceuticals Holdings, Inc. has a 52 week low of $4.64 and a 52 week high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last released its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.24. As a group, equities analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CRBP. Wedbush reiterated an "outperform" rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. Jefferies Financial Group dropped their price target on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. William Blair began coverage on Corbus Pharmaceuticals in a research note on Friday, February 28th. They issued an "outperform" rating for the company. StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday, March 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 target price (down from $75.00) on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $59.13.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.